Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase- Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

Basit Öğe Kaydı
dc.contributor.authorKatgi, Nuran
dc.contributor.authorCimen, Pinar
dc.contributor.authorAkyol, Murat
dc.contributor.authorGursoy, Pinar
dc.contributor.authorAguloglu, Nursin
dc.date.accessioned2024-03-09T18:48:50Z
dc.date.available2024-03-09T18:48:50Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractOBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lym-phoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib's efficacy in the treatment and its place in the first-line treatment and report our real-life data. MATERIAL AND METHODS: The data of 38 patients who were diagnosed with anaplastic lymphoma kinase-positive nonsmall cell lung carcinoma in our clinic between 2016 and 2021, who did not receive any treatment before were retrospectively analyzed. RESULTS: Of the 19 patients who received alectinib, 14 had multiple, and 6 had pretreatment brain metastases. No newly emerging brain metastases were detected during the treatment period. The progression-free survival of patients was 23.5 & PLUSMN; 4.2 months, and overall survival was 24.6 & PLUSMN; 4.1 months. Progression was observed in 10 (52.6%) patients. Of the 19 patients who received crizotinib, 7 had multiple metastases, and brain metastases were detected in 1 patient before treatment and 6 patients during the treatment period. Progression-free survival of crizotinib patients was 17.1 & PLUSMN; 4.8 months and their overall survival was 26.5 & PLUSMN; 6.1 months. Progression was observed in 17 (89.5%) patients. The second line of alectinib could be given to 8 of these patients. Overall survival after second-line treatment of alectinib was 18.2 & PLUSMN; 7.0 months. Overall survival of the patients who could not receive second-line treatment of alectinib was 4.0 & PLUSMN; 2.0 months. CONCLUSION: The progression rate was lower in alectinib than the crizotinib patients, although there were more patients with multiple metastases and brain metastases in the alectinib arm.en_US
dc.identifier.doi10.5152/ThoracResPract.2023.22200
dc.identifier.endpage+en_US
dc.identifier.issn2979-9139
dc.identifier.issue4en_US
dc.identifier.pmid37485706en_US
dc.identifier.scopus2-s2.0-85165946664en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage180en_US
dc.identifier.urihttps://doi.org/10.5152/ThoracResPract.2023.22200
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1502
dc.identifier.volume24en_US
dc.identifier.wosWOS:001048621100002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofThoracic Research and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonsmall Cell Lung Carcinoma; Anaplastic Lymphomakinase Mutation; Alectinib; Crizotinib; Brain Metastasisen_US
dc.titleComparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase- Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectiniben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1502.pdf
Boyut:
411.33 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu